Levofloxacin Unimed Pharma (Levofloxacin Hemihydrate)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By inhibiting these targets, the drug prevents bacterial cell division and leads to bacterial cell death, providing a bactericidal effect against susceptible ocular pathogens.

The dosage regimen for Levofloxacin Unimed Pharma is determined by the prescribing clinician based on the severity of the infection, the patient’s age, renal function and other clinical factors. The prescriber selects the appropriate number of drops and frequency according to established guidelines.

Safety data for levofloxacin use during pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient before prescribing.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Levofloxacin Unimed Pharma. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levofloxacin offers broad‑spectrum activity against Gram‑negative and Gram‑positive bacteria and penetrates ocular tissues well. Compared with older agents such as ciprofloxacin, it often requires fewer daily doses and may have a lower resistance profile, making it a preferred choice for many bacterial eye infections.

Store the ophthalmic solution at room temperature, away from direct sunlight and moisture. Keep the bottle tightly closed in its original packaging until use. Do not freeze the product, and discard any solution that appears discolored or cloudy.

Levofloxacin is applied as eye drops. The patient should wash their hands, tilt the head back, pull down the lower eyelid, and instill the prescribed number of drops into the conjunctival sac. If using contact lenses, they should be removed before instillation and re‑inserted after the drops are absorbed.

Serious risks include severe allergic reactions such as eyelid swelling, hives or anaphylaxis, and rare progression of corneal ulcer despite therapy. Systemic fluoroquinolone‑related effects, such as tendon rupture, have been reported, though they are extremely uncommon with topical ocular use.

Patients with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the ophthalmic formulation should avoid this product. It is also contraindicated in individuals receiving concurrent systemic fluoroquinolone therapy due to additive toxicity risk.